Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Unknown 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 16 Radiotherapy 7 apatinib 5 anlotinib 3 Surgical Procedures, Operative 3 Chlorotoxin 3 Bevacizumab 3 Aminolevulinic Acid 3 Positron Emission Tomography Computed Tomography 2 Pemetrexed 2 Magnetic Resonance Spectroscopy 2 Lomustine 2 Irinotecan 2 Immunotherapy, Adoptive 2 Blood Specimen Collection 2 vandetanib 1 sodium thiosulfate 1 ribociclib 1 poly ICLC 1 lonafarnib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 etoposide phosphate 1 Vinblastine 1 Valproic Acid 1 Tranexamic Acid 1 Surveys and Questionnaires 1 Sunitinib 1 Rivaroxaban 1 Radiosurgery 1 Radiation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Glioma × OKN 007 × Clear all

NCT01672463 2023-03-29

OKN-007

Oblato, Inc.

Phase 1 Unknown

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡